The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1).
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Pfizer
Research Funding - Eisai
 
XiWen Bi
Consulting or Advisory Role - AstraZeneca
 
Guangyu Liu
No Relationships to Disclose
 
Sung Hoon Sim
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Hanmi; Lilly; medpacto; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Novartis; Roche/Genentech
Other Relationship - Roche
 
Shintaro Takao
No Relationships to Disclose
 
Kun Wang
No Relationships to Disclose
 
Young-Hyuck Im
No Relationships to Disclose
 
Manabu Futamura
No Relationships to Disclose
 
Sung Gwe Ahn
No Relationships to Disclose
 
Jeong Eon Lee
No Relationships to Disclose
 
Yeon Hee Park
No Relationships to Disclose
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genomic Health; Konica Minolta; Kyowa Hakko Kirin; Lilly; Novartis; Pfizer; Shimadzu; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Konica Minolta; Kyowa Hakko Kirin
Speakers' Bureau - AstraZeneca; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Shimadzu; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Travel, Accommodations, Expenses - Eisai; Takeda
Other Relationship - Japan Breast Cancer Research Group; Japan Breast Cancer Research Group; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research
 
Yasuhiro Fujiwara
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Santen; SRL Diagnostics
 
Mari Saito-Oba
Consulting or Advisory Role - Daiichi Sankyo (Inst)
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medicon (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Masahiko Nishiyama
No Relationships to Disclose
 
Shigeru Imoto
Consulting or Advisory Role - Daiichi Sankyo